COLO B Coloplast A/S Class B

Coloplast Launches New Catheter in the U.S.

Coloplast Launches New Catheter in the U.S.

Coloplast’s SpeediCath® Flex Set catheter developed for people living with bladder and urinary problems is now cleared in the U.S. and will be launched in November 2022.  

The new SpeediCath Flex Set with a “no touch dry sleeve” and an omni-directional tip is available as a catheter and bag solution, also called a Closed System. All SpeediCath® catheters feature Triple Action Coating Technology which is designed to reduce the risk of urethral damage and Urinary Tract Infections (UTIs)*1 and are an option for those with spinal cord injuries (SCI).

“With SpeediCath Flex Set, we are introducing an important solution for people living with SCI and many other health conditions. We are confident that its new innovative design will make a big difference to our users, improving their catheterization routine in many ways,” says Senior Vice President Manu Varma, Chronic Care in North America.

A recent estimate2 shows that the annual incidence of SCI is about 18,000 cases each year in the U.S. and the majority of the SCI patients will suffer from Neurogenic Bladder Dysfunction (NBD). Patients with NBD have significant challenges to their well-being, ranging from incontinence, renal impairment, and urinary tract infections to bladder stones and a generally poor quality of life.3

The SpeediCath Flex Set is a gentle, all-in-one solution. It has features that help patients confidently catheterize at home or away, supporting them in managing their condition and maintaining a healthy lifestyle. Find more information about SpeediCath Flex Set .

About Coloplast’s Continence Care Products 

Coloplast aims to deliver effective solutions for bladder and bowel control. By continuously gathering feedback from clinicians and patients, the company innovates to solve urinary problems such as incontinence and retention. Coloplast also offers additional support through its Coloplast® Care program, which provides product and lifestyle advice, inspiration, and education resources for people living with bladder issues.

About Coloplast 

Danish medical device company Coloplast develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to end-users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions. Visit for more information. 

 



This information is intended to be an educational resource and presented for general information purposes only. It is not intended to constitute medical or business advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any patient needs or circumstances. Prior to use, please refer to the product ‘Instructions for Use’ for the intended use and relevant safety information.

* Compared to uncoated catheters

  1. Rognoni C, Tarricone R. Intermittent catheterization with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urol. 2017 Jan 10;17(1):4. doi: 10.1186/s12894-016-0191-1.PMID: 28073354; PMCID: PMC5225586.
  2. The National Spinal Cord Injury Database, 2020 SCI Datasheet

Global press contact 

Peter Mønster, Senior Media Relations Manager 

 



    

U.S. press contact 

Kate Merwin, Head of Communications 

612-286-2455 

 



EN
18/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 Sep...

Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025 The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts an introductio...

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch